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 Abstract (199/200 words) 22 
Women with uncomplicated urinary tract infection (UTI) symptoms are commonly treated with empirical 23 
antibiotics, resulting in overuse of antibiotics, which promotes antimicrobial resistance. Available 24 
diagnostic tools are either not cost-effective or diagnostically sub-optimal. Here, we identified clinical and 25 
urinary immunological predictors for UTI diagnosis. We explored 17 clinical and 42 immunological potential 26 
predictors for bacterial culture among women with uncomplicated UTI symptoms using random forest or 27 
support vector machine coupled with recursive feature elimination. Urine cloudiness was the best 28 
performing clinical predictor to rule out (negative likelihood ratio [LR−] =0.4) and rule in (LR+ =2.6) UTI. 29 
Using a more discriminatory scale to assess cloudiness (turbidity) increased the accuracy of UTI prediction 30 
further (LR+ =4.4). Urinary levels of MMP9, NGAL, CXCL8 and IL-1β together had a higher LR+ (6.1) and 31 
similar LR− (0.4), compared to cloudiness. Varying the bacterial count thresholds for urine culture positivity 32 
did not alter best clinical predictor selection, but did affect the number of immunological predictors 33 
required for reaching an optimal prediction. We conclude that urine cloudiness is particularly helpful in 34 
ruling out negative UTI cases. The identified urinary biomarkers could be used to develop a point of care 35 
test for UTI but require further validation. 36 
 Introduction (main text word count 2609) 37 
Most guidelines for uncomplicated UTI recommend treatment with empirical antibiotics. However, when 38 
urine is cultured, approximately only one in three women with UTI symptoms are found to have a UTI as 39 
defined by a positive bacterial culture.1 Therefore, prescribing empirically may result in antibiotic overuse 40 
and contribute to development of antimicrobial resistance. Clinicians generally base treatment decisions 41 
on symptoms, urine appearance, urine dipstick results, risk factors for development of complications and 42 
patient preference2,3. Some of these features have been combined into clinical prediction rules, but the 43 
predictive values remain suboptimal4. Therefore, the development of better diagnostic tools for UTI is 44 
essential for improving antimicrobial stewardship. 45 
Exploratory approaches to aid UTI diagnosis have been based on serum and urinary biomarkers. The 46 
specificity of blood immune markers is limited by the possibility of cross-reactivity due to other infections 47 
or inflammatory responses. Urinary biomarkers that might reflect local immunological responses by the 48 
bladder epithelium include nerve growth factor (NGF), chemokines including IL-8/CXCL85,6, and 49 
antimicrobial peptides (AMPs)7 human α-defensin 5 (HD5)7 and neutrophil gelatinase-associated lipocalin 50 
(NGAL)8. However, there is a lack of comprehensive biomarker screening studies for UTI. 51 
With an expansion in the list of potential UTI biomarkers, it is also important to identify the most useful 52 
and readily available clinical information that could assist UTI diagnosis and guide prescribing decisions at 53 
the point of care. Many studies have implemented multivariate statistical models such as logistic 54 
regression to identify UTI clinical predictors2,4. These models are bound by relationship assumptions 55 
between predictors and outcome variables. In this study we aimed to use a machine learning-based 56 
approach, in which random forest (RF) and support vector machines (SVM) were implemented to allow 57 
fewer assumptions and more complex relationships between predictors. We combined these algorithms 58 
with recursive feature elimination (RFE) to extract the best predictor(s) for uncomplicated UTI using clinical 59 
information and potential biomarkers present in urine. These analytical approaches have been widely used 60 
in medical applications, such as drug discovery, biomarker selection and early diagnosis9-16. SVM, for 61 
instance, is a supervised learning model based on statistical learning for classification and regression 62 
 analysis, which finds the separating hyperplane with the maximal margin between data from different 63 
groups. RF is an ensemble learning method that constructs a multitude of decision trees17 and is a popular 64 
approach for diagnosis18 and medical decision support systems19. Both SVM and RF outperform other 65 
machine learning methods for discriminant problems20. In this study, the aim was to find the best 66 
biomarker for UTI diagnosis, thus the classification ability was an important factor in differentiating UTI 67 
groups. Also, considering the complexity of the raw data required for biomarker discovery, the ability to 68 
cope with high-dimensional data was another criterion in choosing machine learning methods. In RF, the 69 
trees are decorrelated at each split on a small subset of features rather than all features, thus it is a strong 70 
candidate algorithm for high dimensional data. For SVMs, the separate hyperplane relies on the support 71 
vectors not all data, thus giving it independent advantages in dealing with high-dimensional data. 72 
Results 73 
Clinical information to predict UTI  74 
Our study cohort included 183 women who participated in the POETIC (Point of care testing for urinary 75 
tract infection in primary care) trial. They ranged in age from 18 to 85 years, and the key UTI symptoms of 76 
urgency, frequency and dysuria were present in 84.2%, 91.8% and 77.0% of patients, respectively. The 77 
frequency of other symptoms is presented in Table 1. Following urine culture and according to the POETIC 78 
protocol, 79 (43.2%) and 104 (56.8%) patients were classified as UTI positive and negative, respectively. 79 
Data from 128 patients (70%) were used for model training while data from 55 patients (30%) were used 80 
for testing model performance.  81 
Using only the clinical data recorded during the initial consultation, urine cloudiness was the best clinical 82 
predictor for UTI with an area under the ROC curve (AUC) of 0.72 (95% CI 0.60-0.85), positive predictive 83 
value (PPV) 0.65, negative predictive value (NPV) 0.79, positive likelihood ratio (LR+) 2.55, negative 84 
likelihood ratio (LR−) 0.37 and F1 score of 0.69 on the test data subset (Table 2). We then substituted 85 
cloudiness (measured as a binary yes/no) with a more discriminatory assessment of cloudiness (turbidity 86 
score with three categories; Table 1). This substitution resulted in a similar AUC of 0.73 (95% CI 0.60-0.85) 87 
and improved PPV 0.76 and LR+ 4.38 (Table 2). No other clinical features or age added to the predictive 88 
 value of cloudiness/turbidity. RF and SVM algorithms produced similar results, except that SVM selected 89 
age plus turbidity (Table 2).  90 
Urinary biomarkers to predict UTI 91 
We previously reported correlations between bacterial infection and defined immune signatures (‘immune 92 
fingerprints’) in other scenarios21,22. To apply this knowledge to the diagnosis of uncomplicated UTI we 93 
conducted a comprehensive analysis of 42 inflammatory biomarkers in urine samples. In line with earlier 94 
observations, we found positive correlations between many of the immunological biomarkers measured 95 
(supplementary Figure S1). As a consequence, RFE was employed to select the best biomarkers for 96 
predicting UTI. Using the RFE coupled with RF algorithm (RF+RFE), IL-1β and MMP9 were selected as the 97 
best predictors with AUC of 0.82 (95% CI 0.69-0.94) and F1 score of 0.67 on the test data subset (Table 2). 98 
The diagnostic relevance of IL-1β and MMP9 was corroborated in an independent analysis using the 99 
SVM+RFE algorithm, which resulted in the selection of the same urinary biomarkers alongside NGAL and IL-100 
8/CXCL8, with a similar AUC and improved LR+ and F1 score, compared to the RF+RFE selection (Table 2). 101 
Adding the selected immunological biomarkers to the model with clinical features (including cloudiness or 102 
turbidity) did not improve the predictive properties (Table 2). We conclude that while urine cloudiness was 103 
the most useful clinical predictor to rule out negative cases, urinary biomarkers were particularly helpful to 104 
predict the presence of UTI in symptomatic women. 105 
Variable UTI classification guidelines 106 
Finally, we explored whether changing the bacterial count threshold (based on different national and 107 
European UTI guidelines) would affect the selection of clinical and immunological predictors. Using the 108 
Public Health England (PHE) guidelines23,24 to interpret urine culture results, 99 (54.1%) and 84 (45.9%) 109 
patients were UTI positive and negative, respectively. The European Association of Urology (EAU) 110 
guidelines25 classed 118 (64.5%) and 65 (35.5%) as positive and negative, respectively. 111 
Cloudiness/turbidity remained the best clinical predictor when using the PHE or EAU definitions of UTI 112 
positivity (supplementary Table S1). However, the selection of immunological markers varied with UTI 113 
classification and the type of machine learning algorithm employed. Using PHE classification, the best 114 
 predicting model included a combination of urine cloudiness and NGAL, which resulted in a LR+ and LR− of 115 
4.94 and 0.25 respectively, and a good F1 score of 0.82 (Table S1). Using the EAU classification, the 116 
combination of turbidity, feeling unwell, foul smell in urine, NGAL and MMP9 resulted in a model with the 117 
best predictive properties (Table S1).  118 
Discussion 119 
This is one of the first studies to use machine learning methods to select clinical features and urinary 120 
immunological markers to predict culture results for uncomplicated UTI in primary care. We found that 121 
cloudiness of urine samples was the best clinical predictor of microbiologically confirmed UTI among 122 
symptomatic women, and that assessing cloudiness using a categorical turbidity scale improved the 123 
predictive properties further, particularly in identifying positive UTI. We identified a set of four urinary 124 
immunological markers (MMP9, NGAL, IL-8/CXCL8 and IL-1β), which performed slightly better than 125 
cloudiness/turbidity when used independently. Changing the definition of UTI positivity to that used by 126 
PHE and the EAU standards, and using both RF and SVM algorithms, resulted in some changes to 127 
predictors, but urine cloudiness/turbidity, and the immunological markers MMP9, IL-1β and NGAL 128 
continued to be important predictors, thereby confirming their relevance in UTI diagnosis. 129 
While normal urine samples are usually clear, white blood cells (WBCs), red blood cells, epithelial cells, 130 
proteins, crystals, drugs and microorganisms can cause the urine to become cloudy. In uncomplicated UTI, 131 
the presence of WBCs and/or bacteria in urine can lead to urine cloudiness. This is consistent with the 132 
findings of our study where urine cloudiness/turbidity consistently came out as the best predictor of UTI. 133 
This finding is in keeping with previous studies that investigated urine appearance as part of clinical rules 134 
to predict UTI in community settings4 and catheterized patients26. 135 
Visual assessment of urine cloudiness by health care staff is recommended in some guidelines as a step in 136 
the process of diagnosing uncomplicated UTI (for example PHE)27. Our results highlight the importance of 137 
implementing this guideline in ruling out negative UTI cases, which is helpful for antibiotic stewardship 138 
activities. Furthermore, the improvement on positive UTI prediction by using a turbidity score, instead of 139 
binary cloudiness, indicates that the assessment of the degree of cloudiness could improve the diagnosis of 140 
 uncomplicated UTI within a consultation. In our study, turbidity scores were assessed by the microbiology 141 
laboratory after samples were transported from GP practices by standard post at room temperature. As 142 
urine turbidity may decrease or increase with prolonged transportation due to WBC lysis or bacterial 143 
growth, respectively, our samples were preserved in boric acid to protect WBCs and prevent bacterial 144 
growth during transportation28,29. Of note, we found no correlation between transportation time and 145 
turbidity score, indicating that boric acid preservation was sufficient to stabilise the samples (data not 146 
shown).  147 
Cloudiness has not yet been used in other studies using machine-learning for UTI prediction. Heckerling 148 
and colleagues used neural networks with genetic algorithm feature selection to examine 212 women with 149 
suspected UTI30. While they found that cloudiness was associated with increased LR+, their genetic 150 
algorithm did not retain it for the creation of the neural network.  It is possible that this reflects differences 151 
between neural networks and RF models.  Alternatively, it may reflect differences in the cohort, since the 152 
ratio of cloudy:clear urines differed significantly between the two cohorts (current study cloudy:clear ratio 153 
1.13:1, Heckerling et al. 5.84:1), suggesting an underlying difference in the data informing the model. 154 
Taylor et al. also recently used machine learning to predict UTI31. They employed the XGBoost machine 155 
learning approach with 211 clinical variables to develop models predicting UTI in an emergency 156 
department setting. These were reduced to 10 variables (including urine analysis WBCs, bacteria, blood 157 
and dysuria) based on expert knowledge and literature reviews. While this approach worked well, it is not 158 
suitable for use in primary care given the number of recommended predictors. These studies, along with 159 
ours, demonstrate the potential of machine learning algorithms to enhance diagnosis. They also show that 160 
the context of the model is vitally important for its utility and that models may need to be customised for 161 
end users’ settings. 162 
Predictor selection methods provide an advanced statistical tool to identify markers for infectious diseases 163 
but have not yet been widely used22. Using a RFE method coupled with either RF or SVM enabled us to 164 
simultaneously screen 17 clinical and 42 immunological biomarkers to identify predictors of UTI in 165 
symptomatic women in primary care. Nevertheless, we acknowledge that the relatively small sample size 166 
 of our study in relation to the number of screened predictors may result in some instability of estimates 167 
and overfitting. While RFE is known to be particularly robust against overfitting32, we minimised this risk by 168 
using cross-validation in addition to a good hyperparameter search strategy within each model. During 169 
cross-validation, the model was trained on the training set and validated on a subset of the training data at 170 
each iteration, which ensured the generalization performance of the model for unseen data33. 171 
Furthermore, the classifier was trained on all possible combinations of features including the full feature 172 
set and the best combination of features (depending on the generalization performance of the model 173 
through cross validation) was selected as the searching space for the next step. Moreover, models were 174 
tested on an unseen test data set, which was randomly split prior to model training, indicating model 175 
generalizability to an independent data set. 176 
The most promising immunological biomarkers identified were MMP9, NGAL, IL-8/CXCL8 and IL-1β as 177 
selected by SVM+RFE, while RF+RFE selected only IL-1β and MMP9 but with lower LR+ compared to 178 
SVM+RFE. In general, RF identifies the strongest predictors while SVM tends to produce stronger models 179 
based on a larger number of weaker predictors. The fact that we used two machine learning algorithms for 180 
predictors selection increased the confidence in markers that were selected by the two algorithms. There 181 
might be a potential for improvement in the future by using ensemble methods other than RF, however 182 
given that both RF and SVM found turbidity/cloudiness, MMP9 and IL-1β to be the best predictors of UTI it 183 
is likely that these predictors will remain as the most important markers. Ideally, we would be able to 184 
verify these as predictors using a large independent cohort, and we encourage further large studies to 185 
validate our findings. It is also interesting to note that the identified immunological markers interact with 186 
each other during urological infection by restricting bacterial growth and mediating trans-epithelial 187 
movement of neutrophils34. IL-1β induces renal production of NGAL in mice model experiments35, and 188 
NGAL modulates MMP9 activity by protecting it from degradation36. MMP-9, NGAL and some interleukins, 189 
have been previously studied as potential biomarkers for UTI, particularly in infants and children, however, 190 
conclusions were contradictory37-42. 191 
 Urine culture is an imperfect gold standard to identify UTI. Bacterial pathogens may die during transport, 192 
may not grow using conventional culture techniques or may be rendered unidentified due to 193 
contamination of urine samples during collection. There are also differences in opinion on the threshold 194 
used to identify significant growth, reflected in different microbiological guidelines. This has a direct impact 195 
on the reported prevalence of the disease and subsequently on the evaluation of new tools for UTI 196 
diagnosis. This has been shown in this study, as variable numbers of immunological markers were required 197 
to reach the optimum prediction depending on the underlying threshold guidelines applied. 198 
This study involved women who participated in the POETIC trial, and who had excess urine samples 199 
available following the microbiological analyses included in the POETIC study protocol. No other selection 200 
criteria were applied and therefore this should be a relatively representative sample of women presenting 201 
in primary care with UTI. We found a slightly higher prevalence of positive UTI (43%) in our study 202 
compared to the full trial population (35%), but this is likely to be a chance finding and is unlikely to affect 203 
the generalisability of our results. Unfortunately, we were not able to compare urine cloudiness/turbidity 204 
or immunological markers with the point of care urine dipstick most commonly used in primary care, as 205 
dipstick results were not recorded in the POETIC trial. However, previous studies with similar 206 
uncomplicated UTI inclusion criteria, found that dipsticks predicted UTI culture results with a PPV between 207 
0.63 and 0.94 and NPV between 0.20 and 0.81 depending on the diagnostic rule used (presence of nitrite, 208 
leukocytes esterase or both) and urine culture colony count threshold4,43. When dipstick results were 209 
based on leukocytes esterase results only, the maximum PPV and NPV was 0.86 and 0.72, respectively43. In 210 
our study, cloudiness achieved a comparable NPV of up to 0.79, while MMP9, NGAL, IL-8/CXCL8 and IL-1β 211 
achieved PPV of 0.82. 212 
In conclusion, we found that urine cloudiness was the best clinical predictor of UTI among symptomatic 213 
women, and that grading cloudiness using a turbidity score may improve the predictive value further. We 214 
also found that MMP9, NGAL, IL-8/CXCL8 and IL-1β in urine may be useful predictors of UTI. These 215 
biomarkers could be used to develop a new point of care test for UTI, subject to validation of our findings 216 
 in a larger population, across different age groups, using freshly collected urine and a stringent 217 
determination of cut-off levels for the individual biomarkers.  218 
Methods 219 
Patient population and clinical data 220 
Clinical information and urine samples were collected as part of a two-arm randomized controlled trial, 221 
POETIC (Trial number: ISRCTN65200697)23,44. The current analysis included participants from England and 222 
Wales who had excess urine sample following the initial POETIC microbiology experiments. The POETIC 223 
study included women who presented in primary care with at least one key UTI symptom (dysuria, urgency 224 
and frequency) that had been present for up to 14 days. Exclusion criteria were pregnancy, signs of 225 
complicated UTI, current use of antibiotics and functional or anatomical genitourinary tract 226 
abnormalities44. Clinical data were collected by general practitioners (GPs). Main UTI symptoms were 227 
recorded as present/absent and on a scale from 0 (not affected) to 6 (as bad as possible) to measure its 228 
severity. Severity of other symptoms such as fever, flank or abdominal pain, blood in urine, unpleasant 229 
urine smell, restricted activity and feeling unwell were also measured (Table 1). Urine cloudiness 230 
(clear/cloudy) was reported by GPs following sample examination.  231 
Ethics 232 
Informed consent was obtained from each patient involved in the study as part of the POETIC clinical trial 233 
(number: ISRCTN65200697). Ethical approval was given by the Research Ethics Committee (REC) For Wales 234 
recognised by the United Kingdom Ethics Committee Authority (UKECA), REC reference 12/WA/0394. This 235 
study was conducted in accordance with the principles of the Declaration of Helsinki.  236 
Sample collection, processing and culture 237 
Mid-stream urine samples were collected at the GP clinic in a universal container containing boric acid and 238 
sent to the microbiology laboratory (Specialised Antimicrobial Chemotherapy Unit, University Hospital of 239 
Wales, Cardiff) by post. Average time from sample collection to processing in the laboratory was 2.2 240 
[SD=1.4] days. Urine turbidity was scored by microbiology staff, and for the current analysis, it was 241 
categorised as: 1 (clear or slightly turbid), 2 (moderately turbid) and 3 (very turbid). Urine samples were 242 
 then analysed microscopically and cultured on Columbia Blood Agar (CBA) and CHROMagar UTI Orientation 243 
media (E&O) at 34-36oC for 18-20 hrs45. Total and species-specific colony counts were enumerated from 244 
CBA and chromogenic agar, respectively. UTI culture positivity was defined as per the POETIC study 245 
protocol (Box 1). 246 
Urinary immune biomarker procedure 247 
Cell-free urines were analyzed on a SECTOR Imager 6000 (Meso Scale Discovery) using the V-PLEX Human 248 
Cytokine 30-Plex Kit to measure levels of IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-10, IL-12p40, IL-12p70, IL-249 
13, IL-15, IL-16, IL-17A, IFN-γ, TNF-α, TNF-β, GM-CSF, VEGF, CCL2, CCL3, CCL4, CCL11, CCL13, CCL17, CCL22, 250 
CCL26, CXCL8 and CXCL10, and using an ultrasensitive single-plex assays for sIL-6R. Conventional ELISA kits 251 
were used to measure creatinine, cystatin C, HSA, MMP8, MMP9 and RBP4 (R&D Systems) as well as 252 
fibrinogen (Abcam). HNE was measured using a B.I.T.S. ELISA kit (Mologic); activated PGP, desmosine, 253 
FMLP and NGAL were measured using validated in-house developed ELISA kits (Mologic). 254 
Statistical analysis  255 
Data: Our cohort included 183 women with uncomplicated UTI symptoms. For these patients we matched 256 
17 clinical and 70 immunological predictors using patient ID, date of birth and sample ID. There were no 257 
missing data on the outcome variable (UTI classes) or the clinical data, however, 28 immunological 258 
predictors had missing data of >5% and were therefore removed from the subsequent analysis. Missing 259 
data <5% were imputed using Multiple Imputation by Chained Equations in R package “mice” using all 260 
variables except the outcome. Imputation methods were predictive mean matching, logistic regression and 261 
proportional odds model for numeric variables, binary variables and ordered factor variables, 262 
respectively46. UTI classes were defined based on the POETIC guidelines for UTI classification (Box 1). 263 
Alternative UTI classification guidelines by PHE23,24 and the EAU25 were used in sensitivity analyses to 264 
explore if changing bacterial count threshold for positive UTI would change the marker selection. 265 
Analysis approach: We used the RFE Algorithm 2 on “caret” R package platform47, which was coupled with 266 
either RF48 or SVM (radial basis function kernel in “kernlab” R package)49 algorithms to select the best 267 
clinical and immunological predictors. RF+RFE and SVM+RFE models were trained on the clinical and 268 
 immunological predictors separately (Figure 1). Models were trained on all possible combinations of 269 
features including the full feature set and the best combination of features was selected (supplementary 270 
Figure S2). Following the selection of the best clinical and immunological predictors, we aimed to evaluate 271 
the additive predictive value of the selected immunological markers on the selected clinical predictors. 272 
Thus, we merged the selected clinical and immunological predictors and used them to train RF and SVM 273 
models (Figure 1). Merging the selected clinical and immunological markers was conducted only when a 274 
small number of immunological markers were selected.  275 
Data pre-processing: For SVM, which does not recognize nominal variables, both binary and ordinal 276 
categorical variables were transformed by integer encoding, in which naturally ordered integer numbers 277 
were assigned to the levels of the categorical variables to keep the natural order of the clinical data. In 278 
addition, continuous data were standardized to a mean of 0 and a variance of 1 for SVM models50. For RF 279 
models, categorical variables were not transformed because RF can learn directly from categorical data 280 
with no data transformation required. 281 
Model training and testing: Our data included 183 cases that were randomly split into training (70%) and 282 
test (30%) subsets while maintaining the proportion of cases with positive UTI. For all training models, 283 
three repeats of 10-fold cross-validation were used to avoid overfitting. During cross-validation, the model 284 
was trained on the training set and validated on a subset of the training data at each iteration (cross-285 
validation ROC curves are provided in supplementary Figure S3). The random search method in the caret 286 
package50 was implemented to select the optimum hyperparameters (RF: number of features randomly 287 
selected for splitting at each tree node [mtry]; SVM: sigma and Cost soft margin [C]; supplementary Table 288 
S2). Model performance was examined on the unseen test data subset. Model performance was compared 289 
using the following metrics: AUC, PPV, NPV, LR+, LR−51 and F1 Score (harmonic mean of the precision and 290 
recall, which range between 0 and 1 where higher value indicates higher performance)52. For calculating 291 
AUC, the probability threshold for a positive UTI class was set to 0.5. All analyses were performed using R 292 
software version 3.4.253. 293 
Data availability 294 
 Anonymised clinical and immunological data will be available upon request. The corresponding author or 295 
the senior authors (Nick Francis: francisna@cardiff.ac.uk and Chris Butler: 296 
christopher.butler@phc.ox.ac.uk) can receive email requests.  297 
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 Box 1: UTI classification guidelines 
1. POETIC study protocol:29 
• Pure culture of uro-pathogen or potential significant isolate (supplementary Table S3) 
at ≥105 CFU/mL. 
• Pure culture of uro-pathogen or potential significant isolate at >104 and <105 and WBC 
≥30.  
• Mixed culture with predominant uro-pathogen at ≥105 CFU/mL with 3 log difference 
between highest and next species. 
• Mixed culture with two species only, with first uro-pathogen at ≥105 CFU/mL, <3 logs 
difference between the first and second uro-pathogen and WBC ≥30. 
• Mixed culture with two species only, both uro-pathogens at >104 and <105 CFU/mL 
and WBC ≥30. 
• Mixed culture with uro-pathogen at 104 - <105 CFU/mL, ≥3 log difference between 
highest and next species and WBC ≥30. 
2. European Association of Urology 2015 (EAU) guidelines definition of a UTI:33 
• ≥103 CFU/ml of a uro-pathogen. 
 
3. Public Health England (PHE)/Health Protection Agency guidelines: 30,32 
• ≥104 CFU/ml, pure culture of a uro-pathogen. 
• ≥105 CFU/ml, mixed growth with one predominant pathogen. 
• ≥103 CFU/ml, growth of either E. coli or S. saprophyticus  
447 
 Table 1: Frequency of clinical and immunological predictors 
  UTI  
  NO (n=104) YES (n=79) (n=183) 
Patient characteristics, symptoms and urine sample appearance  
    n (%a) n (%a) Total (% b) 
Age category in years 18 – 49 69 (64.5) 38 (35.5) 107 (58.5) 
  50 – 64 26 (60.5) 17 (39.5) 43 (23.5) 
  >65 9 (27.3) 24 (72.7) 33 (18) 
Urgency Absent 18 (62.1) 11 (37.9) 29 (15.8)
  Present 86 (55.8) 68 (44.2) 154 (84.2) 
Frequency Absent 7 (46.7) 8 (53.3) 15 (8.2) 
  Present 97 (57.7) 71 (42.3) 168 (91.8) 
Dysuria Absent 29 (69) 13 (31) 42 (23)
  Present 75 (53.2) 66 (46.8) 141 (77) 
Cloudiness Absent 65 (75.6) 21 (24.4) 86 (47) 
  Present 39 (40.2) 58 (59.8) 97 (53) 
Turbidityc  
 
1  85 (77.3) 25 (22.7) 110 (60.1) 
2 10 (20.4) 39 (79.6) 49 (26.8)
3 9 (37.5) 15 (62.5) 24 (13.1) 
 Fever 
  
  
  
  
  
0 63 (59.4) 43 (40.6) 106 (57.9) 
1 5 (35.7) 9 (64.3) 14 (7.7) 
2 15 (62.5) 9 (37.5) 24 (13.1) 
3 12 (54.5) 10 (45.5) 22 (12)
4 5 (38.5) 8 (61.5) 13 (7.1) 
5 4 (100) 0 (0) 4 (2.2) 
Pain on the sides 
  
  
  
  
  
  
0 48 (57.8) 35 (42.2) 83 (45.4) 
1 7 (70) 3 (30) 10 (5.5)
2 15 (60) 10 (40) 25 (13.7) 
3 9 (45) 11 (55) 20 (10.9) 
4 8 (47.1) 9 (52.9) 17 (9.3) 
5 15 (68.2) 7 (31.8) 22 (12) 
6 2 (33.3) 4 (66.7) 6 (3.3)
Blood in urine 0 78 (55.7) 62 (44.3) 140 (76.5) 
  1 4 (66.7) 2 (33.3) 6 (3.3) 
  2 10 (66.7) 5 (33.3) 15 (8.2) 
  3 8 (66.7) 4 (33.3) 12 (6.6)
  4 1 (25) 3 (75) 4 (2.2) 
   5 3 (50) 3 (50) 6 (3.3) 
Urine foul smell 0 44 (62.9) 26 (37.1) 70 (38.3) 
  1 6 (60) 4 (40) 10 (5.5) 
  2 18 (60) 12 (40) 30 (16.4)
  3 20 (66.7) 10 (33.3) 30 (16.4) 
  4 8 (42.1) 11 (57.9) 19 (10.4) 
  5 5 (55.6) 4 (44.4) 9 (4.9) 
  6 3 (20) 12 (80) 15 (8.2)
Severity of dysuria 0 34 (69.4) 15 (30.6) 49 (26.8) 
  1 4 (66.7) 2 (33.3) 6 (3.3) 
  2 8 (40) 12 (60) 20 (10.9) 
  3 18 (64.3) 10 (35.7) 28 (15.3) 
  4 11 (44) 14 (56) 25 (13.7)
  5 19 (57.6) 14 (42.4) 33 (18) 
  6 10 (45.5) 12 (54.5) 22 (12) 
Severity of urgency 0 13 (68.4) 6 (31.6) 19 (10.4) 
  1 5 (71.4) 2 (28.6) 7 (3.8)
  2 9 (45) 11 (55) 20 (10.9) 
   3 22 (61.1) 14 (38.9) 36 (19.7) 
  4 21 (60) 14 (40) 35 (19.1) 
  5 20 (55.6) 16 (44.4) 36 (19.7) 
  6 14 (46.7) 16 (53.3) 30 (16.4)
Severity of day time 
frequency 
  
  
 
  
0 9 (60) 6 (40) 15 (8.2) 
1 1 (20) 4 (80) 5 (2.7) 
2 10 (62.5) 6 (37.5) 16 (8.7) 
3 21 (58.3) 15 (41.7) 36 (19.7)
4 25 (58.1) 18 (41.9) 43 (23.5) 
5 23 (60.5) 15 (39.5) 38 (20.8) 
6 15 (50) 15 (50) 30 (16.4) 
Severity of night time 
frequency  
  
  
  
  
0 20 (57.1) 15 (42.9) 35 (19.1) 
1 11 (91.7) 1 (8.3) 12 (6.6)
2 12 (70.6) 5 (29.4) 17 (9.3) 
3 20 (52.6) 18 (47.4) 38 (20.8) 
4 17 (50) 17 (50) 34 (18.6) 
5 16 (69.6) 7 (30.4) 23 (12.6)
6 8 (33.3) 16 (66.7) 24 (13.1) 
 Abdominal pain 
  
  
  
  
 
0 33 (55.9) 26 (44.1) 59 (32.2) 
1 7 (41.2) 10 (58.8) 17 (9.3) 
2 15 (75) 5 (25) 20 (10.9) 
3 25 (56.8) 19 (43.2) 44 (24)
4 14 (58.3) 10 (41.7) 24 (13.1) 
5 7 (50) 7 (50) 14 (7.7) 
6 3 (60) 2 (40) 5 (2.7) 
Restricted activity 
  
  
  
  
 
0 40 (58) 29 (42) 69 (37.7)
1 12 (63.2) 7 (36.8) 19 (10.4) 
2 12 (63.2) 7 (36.8) 19 (10.4) 
3 18 (60) 12 (40) 30 (16.4) 
4 10 (43.5) 13 (56.5) 23 (12.6) 
5 9 (60) 6 (40) 15 (8.2)
6 3 (37.5) 5 (62.5) 8 (4.4) 
Feeling generally unwell  
  
  
 
0 29 (65.9) 15 (34.1) 44 (24) 
1 10 (52.6) 9 (47.4) 19 (10.4) 
2 21 (63.6) 12 (36.4) 33 (18)
3 23 (63.9) 13 (36.1) 36 (19.7) 
   4 12 (42.9) 16 (57.1) 28 (15.3) 
5 6 (46.2) 7 (53.8) 13 (7.1) 
6 3 (30) 7 (70) 10 (5.5) 
    Median (Min- Max) Median (Min- Max)  
TEMP   36.7 (35.2 - 39.1) 36.7 (35.3 - 38)   
Immunological markerse  
IL-1α   0.9 (0 - 2.4) 1.4 (0.2 - 3.4)   
IL-1β   1.1 (0 - 2.5) 1.9 (0 - 3.1)   
IL-2   0.2 (0 - 2) 0.4 (0 - 1.7)   
IL-4   0.1 (0 - 0.4) 0.1 (0 - 0.6)   
IL-5   0 (0 - 0.4) 0.1 (0 - 0.4)   
IL-6   0.5 (0 - 2.7) 1.1 (0 - 3.1)   
sIL-6R   2.8 (0 - 3.9) 3.1 (0 - 3.9)   
IL-7   0.3 (0 - 1.2) 0.4 (0 - 1.4)   
IL-10   0.1 (0 - 0.8) 0.2 (0 - 1.1)   
IL-12p70   0.2 (0 - 0.7) 0.3 (0 - 1)   
IL-12p40   0.1 (0 - 1.2) 0.5 (0 - 1.9)   
IL-13   0.7 (0 - 1.6) 1 (0 - 2)   
 IL-15   0.1 (0 - 0.8) 0.2 (0 - 1.6)   
IL-16   0.6 (0 - 2.7) 1.7 (0 - 3.8)   
IL-17A   0.2 (0 - 4.2) 1.4 (0 - 4.2)   
IFN-γ   0.5 (0 - 2) 0.7 (0 - 1.8)   
GM-CSF   0.2 (0 - 2.5) 0.4 (0 - 2.5)   
TNF-α   0.1 (0 - 1.5) 0.4 (0 - 2.3)   
TNF-β   0 (0 - 0.3) 0 (0 - 0.7)   
CCL2   2 (0.6 - 3.4) 2.4 (0.6 - 3.6)   
CCL3   0.8 (0 - 2.3) 1.2 (0 - 3.2)   
CCL4   1.1 (0 - 3) 1.5 (0 - 3.5)   
CCL11   1 (0 - 2.3) 1.2 (0 - 2.6)   
CCL13   0.9 (0 - 2.1) 1.1 (0 - 2)   
CCL17   0.5 (0 - 1.8) 1 (0 - 2.8)   
CCL22   1.2 (0 - 2.5) 1.8 (0 - 3.1)   
CCL26   0.8 (0 - 1.8) 0.9 (0 - 2.2)   
CXCL8   2 (0 - 3.9) 3.1 (0.8 - 4.6)   
CXCL10   1.1 (0 - 4.3) 2.4 (0 - 4.7)   
Creatinine   8.6 (0 - 9.6) 8.8 (4.1 - 9.5)   
 a Percentage out of row total 
b percentage out of total patients (183) 
c 1 = clear or slightly turbid, 2 = moderately turbid and 3 = very turbid 
d Severity of symptoms measured on a scale from 0 (not affected) to 6 (as bad as possible) 
e measured in Pg/ml and values was transformed to log2 
IL: interleukin 
CC or CXC: chemokines  
IFN-γ: interferon-γ 
TNF: tumor necrosis factor 
GM-CSF: granulocyte-macrophage colony-stimulating factor 
VEGF: vascular endothelial growth factor 
Cystatin C   4.4 (0 - 5.4) 4.6 (0 - 5.4)   
Desmosine   4.7 (0 - 6.1) 4.8 (3.1 - 6.5)   
Fibrinogen   4.2 (0 - 5.5) 5.2 (0 - 5.6)   
FMLP   3.7 (0 - 4.4) 3.9 (2.7 - 4.3)   
HNE   5 (0 - 6.4) 5.8 (0 - 6.5)   
HAS   6.7 (0 - 7.4) 7.3 (5.4 - 7.5)   
MMP8   0 (0 - 5.6) 4.6 (0 - 5.6)   
MMP9   0.9 (0 - 5.1) 2.3 (0 - 5.3)   
NGAL   4.5 (0 - 5.9) 5.5 (0 - 5.9)   
Ac-PGP   5.6 (0 - 6.5) 5.6 (0 - 6.3)   
RBP4   4.9 (0 - 6) 5.1 (0 - 6.3)   
VEGF   2 (1.1 - 3.2) 2.4 (1.3 - 3.4)   
 MMP: matrix metalloproteinase  
HNE: human neutrophil elastase  
RBP4: retinol binding protein 4 
NGAL: neutrophil gelatinase-associated lipocalin 
HSA: Human Serum Albumin 
FMLP: N-Formylmethionine-leucyl-phenylalanine 
Ac-PGP: N-acetyl Proline-Glycine-Proline 
 Table 2: Performance of selection and merged models on test data subset 
Data set Algorithm AUC  PPV NPV LR+ LR- F1 score1 Selected predictors 
POETIC UTI classification, UTI prevalence 42.6% 
Clinical markers with cloudiness RF+RFE 0.72  (0.60-0.85)2 
0.65  
(0.44-0.82) 
0.79 
(0.59-0.91) 
2.55 
(1.4-4.6) 
0.37  
(0.18-0.75) 
0.69 
(0.57-0.81) Cloudiness  
Clinical markers with turbidity RF+RFE 0.73  (0.60-0.85) 
0.76 
(0.50-0.92) 
0.73 
(0.56-0.86) 
4.38 
(1.6-11.7) 
0.49 
(0.31-0.80) 
0.65 
(0.52-0.78) Turbidity     
Immunological markers RF+RFE 0.82  (0.69-0.94) 
0.68 
(0.45-0.85) 
0.75 
(0.56-0.88) 
2.88 
(1.41-5.92) 
0.45 
(0.25-0.80) 
0.67 
(0.54-0.80) IL-1β and MMP9  
Selected clinical with cloudiness + 
selected immunological markers  RF 
0.82  
(0.70-0.95) 
0.75 
(0.51-0.90) 
0.76 
(0.58-0.89) 
3.82 
(1.72 -9.52) 
0.42 
(0.23-0.73) 
0.70 
(0.58-0.82) Cloudiness, IL-1β and MMP9 
Selected clinical with turbidity + 
selected immunological markers RF 
0.76  
(0.63-0.90) 
0.67 
(0.43-0.85) 
0.73 
(0.54-0.86) 
2.61 
(1.30 -5.59) 
0.52 
(0.30-0.86) 
0.64 
(0.51-0.77) Turbidity, IL-1β and MMP9 
Clinical markers with cloudiness SVM+RFE 0.73  (0.61-0.85) 
0.65 
(0.44-0.82) 
0.79 
(0.59-0.91) 
2.55 
(1.4-4.6) 
0.37 
(0.18-0.75) 
0.69 
(0.57-0.81) Cloudiness 
Clinical markers with turbidity SVM+RFE 0.86  (0.76-0.96) 
0.76 
(0.50-0.92) 
0.73 
(0.56-0.86) 
4.38 
(1.6-11.7) 
0.49 
(0.31-0.80) 
0.65 
(0.52-0.78) Turbidity and age category  
Immunological markers SVM+RFE 0.81  (0.68-0.94) 
0.82 
(0.55-0.95) 
0.76 
(0.58-0.88) 
6.29 
(2.04-19.36) 
0.43 
(0.26-0.73) 
0.70 
(0.58-0.82) 
MMP9, NGAL, IL-8/CXCL8 and 
IL-1β  
Selected clinical with cloudiness + 
selected immunological markers SVM 
0.82  
(0.70-0.94) 
0.79 
(0.54-0.93) 
0.77 
(0.59-0.89) 
5.00 
(1.93 -13.23) 
0.40 
(0.23-0.71) 
0.71 
(0.58-0.83) 
Cloudiness, MMP9, NGAL, IL-
8/CXCL8 and IL-1β  
Selected clinical with turbidity + 
selected immunological markers SVM 
0.79  
(0.66-0.92) 
0.70 
(0.47-0.86) 
0.77 
(0.58-0.90) 
3.04 
(1.52 -6.24) 
0.39 
(0.31-0.74) 
0.70 
(0.58-0.82) 
Turbidity, age category, MMP9, 
NGAL, IL-8/CXCL8 and IL-1β  
 1 F1 score: harmonic mean of precision and recall 
2 95% confidence interval of the performance metric 
AUC: Area under the curve 
PPV: Positive predictive value 
NPP: Negative predictive value 
LR+ and LR-: positive and negative likelihood ratio 
SVM: support vector machine 
RF: random forest 
RFE: recursive feature elimination 
IL: interleukin 
MMP: matrix metalloproteinase  
NGAL: neutrophil gelatinase-associated lipocalin 
CXCL: the chemokine (C-X-C motif) ligand 
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Figure	1:	Flowchart	of	data	analysis.		
RFE:	recursive	feature	elimina-on	
SVM:	support	vector	machine	
RF:	random	forest	
